10 results match your criteria: "Ronald Reagan UCLA Medical Center (G.C.F.).[Affiliation]"
Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry.
Circ Cardiovasc Qual Outcomes
October 2021
Saint Luke's Mid America Heart Institute, Kansas City, MO (A.T.T., S.V.A., P.G.J., J.A.S.).
Background: Health status outcomes are increasingly being promoted as measures of health care quality, given their importance to patients. In heart failure (HF), an American College of Cardiology/American Heart Association Task Force proposed using the proportion of patients with preserved health status as a quality measure but not as a performance measure because risk adjustment methods were not available.
Methods: We built risk adjustment models for alive with preserved health status and for preserved health status alone in a prospective registry of outpatients with HF with reduced ejection fraction across 146 US centers between December 2015 and October 2017.
Trends in 30- and 90-Day Readmission Rates for Heart Failure.
Circ Heart Fail
April 2021
Department of Medicine, University of Mississippi, Jackson (J.B., M.S.K.).
Background: The impact of hospital readmission reduction program (HRRP) on heart failure (HF) outcomes has been debated. Limited data exist regarding trends of HF readmission rates beyond 30 days from all-payer sources. The aim of this study was to investigate temporal trends of 30- and 90-day HF readmissions rates from 2010 to 2017 in patients from all-payer sources.
View Article and Find Full Text PDFAssessment of Heterogeneity in Heart Failure-Related Meta-Analyses.
Circ Heart Fail
November 2020
Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA (M.V.).
Background: Assessment of heterogeneity in meta-analyses is critical to ensure the consistency of pooled results. Therefore, we sought to assess the evaluation and reporting of heterogeneity in heart failure (HF) meta-analyses.
Methods: Study level meta-analyses pertaining to HF were selected from January 2009 to July 2019, published in 11 high impact factor journals.
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
Circ Heart Fail
September 2018
Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center (G.C.F.).
Background Current guidelines recommend sacubitril/valsartan for patients with heart failure with reduced ejection fraction, but the rate of adoption in the United States has been slow. Methods and Results Using data from CHAMP-HF (Change the Management of Patients With Heart Failure), we described current sacubitril/valsartan use and identified patient, provider, and practice characteristics associated with its use. We considered patients to be on sacubitril/valsartan if they were prescribed it before enrollment or initiated on it at the baseline visit.
View Article and Find Full Text PDFAssociation of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure.
Circ Cardiovasc Qual Outcomes
July 2018
Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (R.K.W., D.L.B.)
Background: Heart failure (HF) is the leading cause of morbidity and mortality in the United States. Despite advancement in the management of HF, outcomes remain suboptimal, particularly among the uninsured. In 2014, the Affordable Care Act expanded Medicaid eligibility, and millions of low-income adults gained insurance.
View Article and Find Full Text PDFTreatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation).
Circ Arrhythm Electrophysiol
November 2017
From the Duke Center for Atrial Fibrillation, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (A.S.B., S.K., L.E.T., E.D.P., J.P.P.); Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center (G.C.F.); Columbia University College of Physicians and Surgeons, New York, NY (J.A.R.); University of Colorado School of Medicine, Aurora (L.A.A.); Yale University School of Medicine, New Haven, CT (J.V.F.); Penn State Hershey Heart and Vascular Institute (G.N.); Stanford University School of Medicine, CA (K.W.M.); Kaiser Permanente Division of Research, Oakland, CA (A.S.G.); Lankenau Institute for Medical Research and Jefferson Medical College, Philadelphia, PA (P.R.K.); Hofstra Northwell School of Medicine, New York, NY (J.E.A.); Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN (B.J.G.); and Boston University Medical Center, MA (E.M.H.).
Background: It is unclear how frequently patients with atrial fibrillation receive guideline-concordant (GC) care and whether guideline concordance is associated with improved outcomes.
Methods And Results: Using data from ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we determined how frequently patients received care that was concordant with 11 recommendations from the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society atrial fibrillation guidelines pertaining to antithrombotic therapy, rate control, and antiarrhythmic medications. We also analyzed the association between GC care and clinical outcomes at both the patient level and center level.
Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes.
Stroke
July 2017
From the Department of Neurology, Southern Illinois University School of Medicine, Springfield (N.I.K., F.M.S.); Department of Emergency Medicine (J.N.G.), Department of Neurology (L.H.S.), Massachusetts General Hospital, and Brigham and Women's Hospital Heart and Vascular Center (D.L.B.), Harvard Medical School, Boston; Duke Clinical Research Institute, Durham, NC (M.C., Y.X., R.A.M., E.D.P.); Department of Medicine (E.D.P.), and Department of Neurology (Y.X.), Duke University Medical Center, Durham, NC; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC (R.A.M.); Department of Medicine, Stanford University School of Medicine, CA (P.A.H.); Department of Medicine, Ronald-Reagan UCLA Medical Center (G.C.F.); and Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada (E.E.S.).
Background And Purpose: Although the use of antiplatelet therapy (APT) is associated with the risk of intracerebral hemorrhage (ICH), there are limited data on prestroke APT and outcomes, particularly among patients on combination APT (CAPT). We hypothesized that the previous use of antiplatelet agents is associated with increased mortality in ICH.
Methods: We analyzed data of 82 576 patients with ICH who were not on oral anticoagulant therapy from 1574 Get with the Guidelines-Stroke hospitals between October 2012 and March 2016.
Substantial Progress Yet Significant Opportunity for Improvement in Stroke Care in China.
Stroke
November 2016
From the Division of Vascular Neurology, Department of Neurology (Z.L., X.Z., C.Z., Yongjun Wang), Tiantan Clinical Trial and Research Center for Stroke, Department of Neurology (Z.L., Chunjuan Wang, H.L., A.W., Y.P., Y.J., X.Y., Yilong Wang), Neurointensive Care Unit, Department of Neurology (L.L.), and Department of Neuropsychiatry and Behavioral Neurology and Clinical Psychology (Chunxue Wang), Beijing TianTan Hospital, Capital Medical University, China; China National Clinical Research Center for Neurological Diseases, Beijing (Yilong Wang, Yongjun Wang); Center of Stroke, Beijing Institute for Brain Disorders, China (Z.L., X.Z.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (Chunjuan Wang); Department of Statistics and Operations Research, University of North Carolina at Chapel Hill (H.S.); Duke Clinical Research Institute (J.B., E.D.P., Y.X.) and Duke University School of Nursing (J.B., Q.Y.), Duke University, Durham, NC; INI Stroke Network, OSF Healthcare System, University of Illinois College of Medicine, Peoria (D.W.); Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan-UCLA Medical Center (G.C.F.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.); and Department of Quantitative Health Sciences, Cleveland Clinic, OH (B.H.).
Background And Purpose: Stroke is a leading cause of death in China. Yet the adherence to guideline-recommended ischemic stroke performance metrics in the past decade has been previously shown to be suboptimal. Since then, several nationwide stroke quality management initiatives have been conducted in China.
View Article and Find Full Text PDFCoenzyme Q10 and Heart Failure: A State-of-the-Art Review.
Circ Heart Fail
April 2016
From the Division of Cardiology, Duke University School of Medicine, Duke Heart Center, Durham, NC (A.S., G.M.F.); Division of Cardiology, Canadian VIGOUR Centre, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton (A.S., J.A.E.); Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center (G.C.F.); and Department of Medicine, Division of Cardiology, Stony Brook University, NY (J.B.).
Heart failure (HF) with either preserved or reduced ejection fraction is associated with increased morbidity and mortality. Evidence-based therapies are often limited by tolerability, hypotension, electrolyte disturbances, and renal dysfunction. Coenzyme Q10 (CoQ10) may represent a safe therapeutic option for patients with HF.
View Article and Find Full Text PDFSmoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke: Findings From Get With The Guidelines.
Circ Cardiovasc Qual Outcomes
October 2015
From the Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston (S.F.A., L.H.S.); Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada (E.E.S.); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.); Duke Clinical Research Institute, Durham, NC (X.Z., Y.X., A.F.H.); Division of Cardiology, Brigham and Women's Hospital Heart and Vascular Institute, Boston, MA (D.L.B.); Harvard Medical School, Boston, MA (D.L.B.); and Division of Cardiology, Ronald Reagan-UCLA Medical Center (G.C.F.).
Background: Smoking is a potent risk factor for coronary artery disease (CAD) and acute ischemic stroke (AIS), but there are numerous reports of lower in-hospital mortality among smokers versus nonsmokers hospitalized for these events.
Methods And Results: We analyzed all consecutive patients hospitalized with a first index CAD (n=158 054) or AIS (n=899 295) event in Get With The Guidelines from 2002 to 2012; 20.4% of AIS and 30.